Publikation

Levetiracetam versus Phenobarbital for Neonatal Seizures: A Retrospective Cohort Study.

Wissenschaftlicher Artikel/Review - 22.10.2022

Bereiche
PubMed
DOI
Kontakt

Zitation
Bättig L, Dünner C, Cserpan D, Rüegger A, Hagmann C, Schmitt B, Pisani F, Ramantani G. Levetiracetam versus Phenobarbital for Neonatal Seizures: A Retrospective Cohort Study. Pediatr Neurol 2022; 138:62-70.
Art
Wissenschaftlicher Artikel/Review (Englisch)
Zeitschrift
Pediatr Neurol 2022; 138
Veröffentlichungsdatum
22.10.2022
eISSN (Online)
1873-5150
Seiten
62-70
Kurzbeschreibung/Zielsetzung

Although phenobarbital (PB) is commonly used as a first-line antiseizure medication (ASM) for neonatal seizures, in 2015 we chose to replace it with levetiracetam (LEV), a third-generation ASM. Here, we compared the safety and efficacy of LEV and PB as first-line ASM, considering the years before and after modifying our treatment protocol.